Given the possible role of adiponectin as a promising therapeutic target against highly prevalent metabolic diseases such as T2D [51], future studies aiming to unravel mechanisms related to FTO rs9939609 regulating plasma adiponectin concentrations different from body adiposity are warranted. This evidence concerns the gene ADIPOQ and metabolic disease.